NASDAQ · Biotechnology

Stoke Therapeutics, Inc. (STOK) Stock

$24.84 +3.73% NASDAQ: STOK Healthcare

Valuation

MetricValue
Price$24.84
Market Cap$1.60B
P/E Ratio-7.74
P/B Ratio4.97
P/S Ratio60.81
EPS (TTM)$-0.12
52-Week High$40.22
52-Week Low$20.32
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-59.36%
ROA-52.77%
ROCE-63.45%
Gross Margin90.36%
Operating Margin-5.77%
Net Margin-753.60%
Debt/Equity0.01
Current Ratio5.28

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$12.0M$9.0M$37.0M$184.0M
Operating Profit$-86.0M$-104.0M$-115.0M$-101.0M$-21.0M
Net Profit$-86.0M$-101.0M$-105.0M$-89.0M$-7.0M
EPS$-2.34$-2.60$-2.38$-1.65$-0.12
Op Margin—-841.2%-1307.2%-277.3%-11.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$239.0M$256.0M$228.0M$272.0M$418.0M
Total Liabilities$21.0M$71.0M$69.0M$43.0M$66.0M
Cash$145.0M$114.0M$191.0M$128.0M$84.0M
Borrowings$5.0M$2.0M$2.0M$5.0M$3.0M

Latest News

Ionis Begins Dosing in Phase I/II Dravet Syndrome Study Zacks · Jul 14, 2026 Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer Business Wire · Jul 13, 2026 Stoke Therapeutics Completes Enrollment in Phase 3 Study of Zorevunersen for Dravet Syndrome Treatment MT Newswires · Jun 30, 2026 Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome Business Wire · Jun 30, 2026 Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire · Jun 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-67.0M$-32.0M$-81.0M$-87.0M$46.0M
Investing Cash Flow$-78.0M$-50.0M$104.0M$-108.0M$-187.0M
Financing Cash Flow$0$1.0M$1.0M$2.0M$0
Net Cash Flow$-142.0M$-31.0M$78.0M$-63.0M$-44.0M
Free Cash Flow$-68.0M$-36.0M$-83.0M$-87.0M$45.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.06
EV / EBITDA-7.65
FCF Yield-10.77%
Quick Ratio7.69
Interest Coverage-4856.02
Return 1Y116.88%
Return 3Y352.86%
Return 5Y-11.75%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $337.01 -1.00% 38.93 $4.95T 0.32%
MSFTMicrosoft Corporation $535.56 +2.48% 28.68 $3.98T 0.76%
GOOGLAlphabet Inc. $351.83 +1.01% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.58 +3.35% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $719.34 -0.22% 27.93 $1.83T 0.28%

About Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. (STOK) stock trades at $24.84 with a market capitalization of $1.60B. The stock is valued at a price-to-earnings (P/E) ratio of -7.74, price-to-book of 4.97, price-to-sales of 60.81. Over the past 52 weeks the stock has ranged between $20.32 and $40.22, and currently trades 38.2% below its 52-week high.

On profitability, Stoke Therapeutics, Inc. generates a return on equity (ROE) of -59.36%, return on capital employed of -63.45%, an operating margin of -5.77%, a net profit margin of -753.60%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1175.87 +0.54% JNJ Johnson & Johnson $261.29 +1.88% ABBV AbbVie Inc. $276.40 +1.46% MRK Merck & Company, Inc. Common Stock (new) $146.30 +2.75% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.88 +2.41% NVS Novartis AG $143.79 +0.47% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $657.57 +0.86% AMGN Amgen Inc. $414.83 +1.81% GILD Gilead Sciences, Inc. $151.22 +2.80% ABT Abbott Laboratories $99.71 +1.23% NVO Novo Nordisk A/S $38.67 +1.27%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides